{"transactions":[{"id":697244,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26665,"kind":"person","name":"Crutcher Patrick J","position":1,"cik":"0001754540","reported_name":"Crutcher Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy","published_at":"2026-08-04T20:10:44.000Z","date":"2026-07-31","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date."}],"balance_after":7500,"derivative":{"exercise_price":0.63,"exercise_date":"2027-07-31","expiration_date":"2036-07-31","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-26-085190","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754540/000121390026085190/ownership.xml","form_type":"4"}},{"id":705804,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26665,"kind":"person","name":"Crutcher Patrick J","position":1,"cik":"0001754540","reported_name":"Crutcher Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Voting Convertible Preferred Stock","published_at":"2026-07-21T00:38:57.000Z","date":"2026-07-20","kind":"purchase","planned":false,"acquired":true,"shares":888,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On July 16, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock (\"Voting Common Stock\"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"On July 16, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026."},{"field":"shares","element":"transactionShares","label":"F3","text":"On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock (\"Voting Common Stock\"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 16, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock (\"Voting Common Stock\"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 16, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock (\"Voting Common Stock\"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On July 16, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock (\"Voting Common Stock\"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date."}],"balance_after":888,"derivative":{"underlying":"Voting Common Stock","underlying_shares":888},"source":{"system":"sec-edgar","filing":"0001213900-26-079764","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754540/000121390026079764/ownership.xml","form_type":"4"}},{"id":705803,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26665,"kind":"person","name":"Crutcher Patrick J","position":1,"cik":"0001754540","reported_name":"Crutcher Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy","published_at":"2026-07-21T00:38:57.000Z","date":"2026-07-16","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares shall vest as follows: 25% on the one-year anniversary of the date of grant and the remaining shares shall vest in equal monthly installments over the next 36 months until fully vested, subject to continuous service through each applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares shall vest as follows: 25% on the one-year anniversary of the date of grant and the remaining shares shall vest in equal monthly installments over the next 36 months until fully vested, subject to continuous service through each applicable vesting date."}],"balance_after":15000,"derivative":{"exercise_price":0.774,"underlying":"Voting Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001213900-26-079764","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754540/000121390026079764/ownership.xml","form_type":"4"}},{"id":3569066,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":26665,"kind":"person","name":"Crutcher Patrick J","position":1,"cik":"0001754540","reported_name":"Crutcher Patrick J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Business Development"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-02T23:28:26.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":145000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months."}],"balance_after":145000,"derivative":{"exercise_price":6.22,"expiration_date":"2029-04-01","underlying":"Common Stock","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0001578563-19-000012","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754540/000157856319000012/primary_doc.xml","form_type":"4"}},{"id":3569065,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":26665,"kind":"person","name":"Crutcher Patrick J","position":1,"cik":"0001754540","reported_name":"Crutcher Patrick J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Business Development"}}],"security":"Common Stock","published_at":"2019-04-02T23:28:26.000Z","date":"2018-12-20","kind":"disposition_to_issuer","acquired":false,"shares":6871,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 1,000,000 shares of Ichorion Therapeutics, Inc. common stock in connection with the merger of Ichorion Therapeutics, Inc. into the Issuer.  On September 25, 2018 the closing price of the Issuer's common stock was $4.55 per share. This transaction reports a disposition of shares to accurately reflect a working capital adjustment."}],"balance_after":1634771,"source":{"system":"sec-edgar","filing":"0001578563-19-000012","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754540/000157856319000012/primary_doc.xml","form_type":"4"}},{"id":3796819,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":26665,"kind":"person","name":"Crutcher Patrick J","position":1,"cik":"0001754540","reported_name":"Crutcher Patrick J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Business Development"}}],"security":"Common Stock","published_at":"2018-10-04T20:56:27.000Z","date":"2018-09-25","kind":"grant","acquired":true,"shares":1641642,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 1,000,000 shares of Ichorion Therapeutics, Inc. common stock in connection with the merger of Ichorion Therapeutics, Inc. into the Issuer.  On September 25, 2018 the closing price of the Issuer's common stock was $4.55 per share."}],"balance_after":1641642,"source":{"system":"sec-edgar","filing":"0001754540-18-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754540/000175454018000001/primary_doc.xml","form_type":"4/A","original_submission_date":"2018-09-27"}},{"id":3806642,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":26665,"kind":"person","name":"Crutcher Patrick J","position":1,"cik":"0001754540","reported_name":"Crutcher Patrick J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Business Development"}}],"security":"Common Stock","published_at":"2018-09-27T20:29:17.000Z","date":"2018-09-25","kind":"grant","acquired":true,"shares":1645286,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 1,000,000 shares of Ichorion Therapeutics, Inc. common stock in connection with the merger of Ichorion Therapeutics, Inc. into the Issuer.  On September 25, 2018 the closing price of the Issuer's common stock was $4.55 per share."}],"balance_after":1645286,"source":{"system":"sec-edgar","filing":"0001578563-18-000015","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754540/000157856318000015/primary_doc.xml","form_type":"4"}}]}